We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 7, 2009
Last Update Posted: June 8, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Aria Aesthetics Inc.
This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.

Condition Intervention Phase
Rosacea Acne Vulgaris Atopic Dermatitis Seborrheic Dermatitis Drug: Topical oxygen Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial

Resource links provided by NLM:

Further study details as provided by Aria Aesthetics Inc.:

Primary Outcome Measures:
  • skin grading evaluation of photodamage [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • stratum corneum hydration (skin capacitance) [ Time Frame: 8 weeks ]
  • bioinstrumental assessment of skin "melanin" lightening, and lesional erythematous sites [ Time Frame: 8 weeks ]
  • bioinstrumental assessment of skin texture, scaliness (desquamation) [ Time Frame: 8 weeks ]
  • punch biopsy histopathologic examination (H&E, and immunohistochemistry for Aquaporin 3, and Filaggrin) [ Time Frame: 8 weeks ]
  • RT-PCR collagenase , and hypoxia-inducible factor-1 alpha [ Time Frame: 8 weeks ]
  • product performance [ Time Frame: 8 weeks ]

Enrollment: 49
Study Start Date: September 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Aria Regimens 0.5% conc
Drug: Topical oxygen
0.5% concentration of Topical oxygen
Experimental: B
Aria Regimen (5 products) 0.25% conc
Drug: Topical oxygen
0.25% concentration topical oxygen
Placebo Comparator: C
Aria Regimen Control without O2
Drug: placebo
no O2


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must be female, 25-60 years old in good general health;
  • Subjects must be Fitzpatrick Types I, II, III, IV, V
  • Subjects must be willing to forgo the use of facial cosmetics (e.g. facial moisturizers,creams, foundations, blush, etc.) during the course of the study.
  • Subjects may ONLY use facial regimen of products provided by sponsor(lipstick, lip gloss, and eye mascara permitted).

Exclusion Criteria:

  • Known sensitivity to any of the test material ingredients.
  • Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted) (one-8lmg or 325mg aspirin okay) (birth control is okay but needs to be reported).
  • Use of topical OTC/Rx drugs or other cosmetics at the test sites.
  • Immunological disorders such as HIV positive and systemic lupus erythematosus (interview only)
  • Participation in any clinical study within the last four weeks.
  • Pregnant or lactating women (interview only).
  • Damaged skin in or around test sites (including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00991198

United States, North Carolina
Dermatology Consultants Inc
High Point, North Carolina, United States, 27262
Sponsors and Collaborators
Aria Aesthetics Inc.
Principal Investigator: Zoe D Draelos, MD Dermatology Consultants Inc.
  More Information

Responsible Party: Larry Rheins, PhD/President, Aria Aesthetics, Inc.
ClinicalTrials.gov Identifier: NCT00991198     History of Changes
Other Study ID Numbers: IFLOTDO002
First Submitted: October 6, 2009
First Posted: October 7, 2009
Last Update Posted: June 8, 2011
Last Verified: June 2011

Keywords provided by Aria Aesthetics Inc.:
Topically dissolved oxygen
inflammatory cutaneous disease
acne vulgaris
atopic dermatitis
seborrheic dermatitis

Additional relevant MeSH terms:
Dermatitis, Atopic
Acne Vulgaris
Dermatitis, Seborrheic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Acneiform Eruptions
Sebaceous Gland Diseases
Skin Diseases, Papulosquamous